Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextromethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.95 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.95 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.95 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.95 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.95 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.95 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.95 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomethorphan SCHEMBL4910539 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL29359586 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL4894005 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL1321395 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4532860 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL30052214 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4882307 | 0.99 | CYP2D6 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121924 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL3325972 | 0.99 | GRIN1 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL6855351 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8050 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144764-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144765-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094687-A | Compounds and combinations thereof for the treatment of neurological and psychiatric disorders | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107265-A1 | PHARMACEUTICAL DOSAGE FORMS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629422-B2 | Agave syrup formulation or suspension for active pharmaceutical agents | GENEXA INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-20260130871-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260124195-A1 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-07 | — | — | US | claimed |
| US-12605348-B2 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | CATALENT ONTARIO LIMITED (CA) | 2026-04-21 | — | — | US | claimed |
| US-12599576-B2 | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan | ANTECIP BIOVENTURES II LLC (US) | 2026-04-14 | — | — | US | claimed |
| US-20260097006-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-04-09 | — | — | US | claimed |
| EP-0281460-A2 | Aqueous compositions containing a cationic compound and xanthan gum | RHONE-POULENC CHIMIE (FR) | 1988-09-07 | — | — | EP | claimed |
| US-4753800-A | DRUGS ADSORBED ONTO MAGNESIUM ALUMINUM STEARATE | WARNER-LAMBERT COMPANY (US) | 1988-06-28 | — | — | US | claimed |
| EP-0241615-A1 | A pharmaceutical composition of phenindamine having enhanced release characteristics | WARNER-LAMBERT COMPANY (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0239361-A1 | Sustained-release pharmaceutical preparation | KINAFORM TECHNOLOGY, INC. (US) | 1987-09-30 | — | — | EP | claimed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | claimed |
| US-4581232-A | ANTITUSSIVE AGENTS, TASTELESS | WARNER-LAMBERT COMPANY (US) | 1986-04-08 | — | — | US | claimed |
| EP-0132472-A1 | Medicated products containing a magnesium trisilicate adsorbent with a medicament drug adsorbed thereon | WARNER-LAMBERT COMPANY (US) | 1985-02-13 | — | — | EP | claimed |
| US-4446140-A | Method and composition for treating mouth pain | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1984-05-01 | — | — | US | claimed |
| EP-0081823-A1 | Composition for reducing menstrual pain | WHITBY RESEARCH, Inc. (US) | 1983-06-22 | — | — | EP | claimed |
| US-4316888-A | Method and composition of reducing pain | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1982-02-23 | — | — | US | claimed |